Misako Nagasaka, Thoracic Oncologist at University of California Irvine, posted on X:
“Another option for patients!!
On June 11, 2025, the FDA approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive NSCLC.”
More posts featuring NSCLC.